Natera (NASDAQ: NTRA) reported Q3 EPS of ($0.49), $0.02 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $65.3 million versus the consensus estimate of $66.43 million.

"We were very pleased to see our pipeline of initial studies with pharma evolving to multiple prospective clinical trials," said Matthew Rabinowitz, Natera's Chief Executive Officer. "With core business growth, enrollment of the 20,000th patient in our SMART trial, progress along our planned reimbursement pathway in transplant, and new data to be released at the San Antonio Breast Cancer Symposium, we continue to make strong progress across the business."

GUIDANCE:

Natera sees FY2018 revenue of $250-280 million, versus the consensus of $263.2 million.

For earnings history and earnings-related data on Natera (NTRA) click here.